Related references
Note: Only part of the references are listed.Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events
Ricky D. Turgeon et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2018)
Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan
Satoshi Kodera et al.
CIRCULATION JOURNAL (2018)
Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease
Manon C. Stam-Slob et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective
Radya Kumar et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases
Parth Shah
CURRENT CARDIOLOGY REPORTS (2018)
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Hmwe Hmwe Kyu et al.
LANCET (2018)
Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting
Max Korman et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2018)
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
Dhruv S. Kazi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016
Mohsen Naghavi et al.
LANCET (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Systematic review of the cost-effectiveness of influenza immunization programs
Eon E. K. Ting et al.
VACCINE (2017)
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
Peter P. Toth et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial
Alejandro Arrieta et al.
JAMA CARDIOLOGY (2017)
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
Gregg C. Fonarow et al.
JAMA CARDIOLOGY (2017)
Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives
Alejandro Arrieta et al.
PLOS ONE (2017)
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
Guillermo Villa et al.
CLINICAL THERAPEUTICS (2017)
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Shravanthi R. Gandra et al.
CLINICAL CARDIOLOGY (2016)
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Dhruv S. Kazi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia
Jennifer G. Robinson
PROGRESS IN CARDIOVASCULAR DISEASES (2016)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ALIROCUMAB: TARGETING PCSK9 TO TREAT HYPERCHOLESTEROLEMIA
I. Pecin et al.
DRUGS OF TODAY (2015)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
